Format

Send to

Choose Destination
Int J Eat Disord. 2012 Mar;45(2):281-9. doi: 10.1002/eat.20946. Epub 2011 Jul 8.

Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial.

Author information

1
Lindner Center of HOPE, Mason, OH, USA. anna.guerdjikova@lindnercenter.org

Abstract

OBJECTIVE:

This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders.

METHOD:

In this 12-week, double-blind, placebo-controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency.

RESULTS:

In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups.

DISCUSSION:

Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.

PMID:
21744377
DOI:
10.1002/eat.20946
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center